Tumor News and Research

RSS

‘Low’ toxicity for phase I cancer trials

Advanced cancer patients participating in phase I clinical trials at the University of Texas MD Anderson Cancer Center experienced a low rate of toxicity, researchers say.

13 Aug 2012

CBIS initiates CS-TATI-1 GMP development plan

Cannabis Science (CBIS), a pioneering U.S. Biotech Company developing pharmaceutical to meet global public health challenges is pleased to announce the initiation of GMP development plan for CS-TATI-1 with the initial production of CS-TATI-1 to be performed in Colorado under C-GMP conditions evaluated by the FDA for initial human studies to treat HIV associated Kaposi Sarcoma.

13 Aug 2012

Radiation therapy following lumpectomy may benefit older, early-stage breast cancer patients

For the majority of older, early-stage breast cancer patients, radiation therapy following breast conserving surgery may help prevent the need for a later mastectomy, according to research from The University of Texas MD Anderson Cancer Center.

13 Aug 2012

Combination therapy does not change safety and efficacy relationship of TORISEL for advanced RCC

Pfizer Inc. announced that the Phase 3 INTORACT trial (B1771006), evaluating the combination of bevacizumab plus TORISEL (temsirolimus) compared with bevacizumab plus interferon-alfa-2a (IFN-α-2a) in the first-line treatment of patients with advanced renal cell carcinoma (RCC) across risk groups, did not meet its primary endpoint of superiority in extending progression free survival (PFS) in the study population.

12 Aug 2012

New subtype of Ewing sarcoma discovered

A new study of the genetic makeup, or genome, of Ewing sarcoma, a rare cancer that strikes children, teenagers, and young adults, has produced multiple discoveries: a previously unknown sarcoma subtype, genetic factors related to long-term survival, and identification of a genetic change between the primary and metastatic stages of the disease that could lead to better, more targeted treatment.

10 Aug 2012

Nematode worms help identify potential cancer targets

Through novel experiments involving small nematode worms, scientists from Wyoming have discovered several genes that may be potential targets for drug development in the ongoing war against cancer. Specifically, researchers hypothesize that inhibiting these genes could reverse certain key traits associated with cancer cells.

10 Aug 2012

Allergies appear to lower brain tumor risk

Testing positive for immunoglobulin E, a biomarker of allergy, reduces a person’s risk for developing glioma, show study findings.

10 Aug 2012

Loyola to offer new radiotherapy system for cancer patients

A new radiotherapy system at Loyola University Medical Center will offer cancer patients shorter radiation treatments, with pinpoint accuracy and precision.

9 Aug 2012

Data from IMUC’s ICT-107 Phase I trial on glioblastoma multiforme accepted for publication

ImmunoCellular Therapeutics announced today that clinical data from its Phase I trial of ICT-107 was accepted for publication, and is currently in the online edition of the prestigious medical journal Cancer Immunology, Immunotherapy.

9 Aug 2012

Theranostic imaging targets and tracks potent drug therapies to prostate cancer cells

Experimenting with human prostate cancer cells and mice, cancer imaging experts at Johns Hopkins say they have developed a method for finding and killing malignant cells while sparing healthy ones.

9 Aug 2012

Pathologist identifies HPV DNA fragments in post-mortem samples after Gardasil vaccination

According to Norma Erickson, President of SaneVax Inc., testimony provided for a coroner's inquest into the death of Jasmine Renata in New Zealand by Dr. Sin Hang Lee, a pathologist on the medical staff at Connecticut's Milford Hospital, revealed the discovery of HPV DNA fragments in post-mortem samples 6 months after Gardasil vaccination.

9 Aug 2012

MedPage Today, CollabRx sign license agreement for Oncology Next

Tegal Corporation today announced that its recently acquired CollabRx, Inc., subsidiary signed an exclusive license agreement to provide a version of its proprietary Therapy Finder tool to MedPage Today, Everyday Health, Inc.'s rapidly growing online site that serves 96% of all oncologists and 1.6 million monthly online unique users.

9 Aug 2012